Newswise — As biotech and healthcare investors focus on turning scientific discoveries into real-world treatments, one critical challenge remains: the “valley of death” between laboratory findings and patient impact.
Dr. William Greene, Chief Investment Officer at Hevolution Foundation, emphasizes the urgent need to invest in translational research that integrates data, technology, and healthcare systems to ensure scientific progress reaches patients.
"Let’s really invest in translation, since there's a valley of death between interesting laboratory observation and something that seems to actually impact health. That is whether it’s biologic observation, a physical observation, chemical observation, or even a sociological observation. So what's the taxonomy of translation, what is the outcome that we're looking for that will actually make humans into big mice? For the purpose of actually predicting an outcome, we need to invest in that. It is time to start looking at companies that are combining data, interpretation of data, and biologic observations. The question is how do we get things delivered to people? We have to put [information and technology] into the context of our healthcare systems and the way our healthcare system works tomorrow, not a fantasy one of the future."
Would you be interested in speaking with Dr. Greene about how to accelerate translational science and make healthcare innovation more accessible?
RSS